BCL2 and melanoma: Models obtained using RapidMiner DTs show that the Breslow index, infiltrating L-BCL2+, and IL-4 levels are associated with a poor prognosis, whereas a decrease in GM-CSF serum levels directly identifies early-stage melanoma patients in whom the disease-free survival is less than 21.5 months.